There’s more to life than
your condition
Alprolix on Demand
You’re often the type to keep your eye on what matters most. And it all starts with staying ahead of your hemophilia B with prophy.

bleed and joint bleed protection* for what’s next

Adults and Adolescents on a prophylactic regimen experienced a median of:

1.38 OVERALL BLEEDS PER YEAR
ON A PROPHY INDIVIDUALIZED INTERVAL (n=26)
2.95 OVERALL BLEEDS PER YEAR
ON A PROPHY FIXED WEEKLY INTERVAL (n=61)
~1 SPONTANEOUS BLEEDS PER YEAR
(n=87)
*ALPROLIX has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.

The overall median annual bleed rate (ABR) was 1.4 bleeds per year (n=26). In the B-LONG study, adults and adolescents who started infusing on a 10-day individualized prophylaxis regimen with ALPROLIX experienced a median annual spontaneous bleed rate (AsBR) of 0.9 bleeds per year.

In the same study, adults and adolescents infusing on a once-weekly prophylaxis regimen with ALPROLIX experienced a median AsBR of 1.04 bleeds per year. The overall median ABR was 3 bleeds per year (n=61).

ADULTS AND ADOLESCENTS:

In the B-LONG study, people infusing prophylactically experienced:
  • A median of 0.36 joint bleeds per year on a prophy individualized interval (n=26)
  • A median of 1.11 joint bleeds per year on a prophy fixed weekly interval (n=61)
  • A median of ~1 spontaneous bleeds per year on a prophylactic regimen (n=87)

TARGET JOINT RESOLUTION

100% target joint resolution in 37 patients

100% TARGET JOINT RESOLUTION IN 37 PATIENTS

37/37 patients who had target joints at the baseline of the B-LONG study achieved target joint resolution with ALPROLIX during the extension study. These subjects had ≥12 months of consecutive follow-up time and did not undergo joint surgery within 12 months of the start of follow-up.

A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 3-month period. Target joint resolution is defined as 2 or fewer spontaneous bleeds in a 12-month period.

B-LONG was a phase 3 study that investigated the safety and efficacy of ALPROLIX in 123 previously treated adult and adolescent patients 12 and older with severe hemophilia B. The study included a fixed-interval (weekly) arm (n=63), a fixed-dose (interval-adjusted) arm (n=29), an episodic (On Demand) arm (n=27), and a surgical arm (n=12).

Interested in extending?
This may help get you started.
"I recommend ALPROLIX to patients many times because I've seen it be successful."
Dr. Guillermo De Angulo, Hematology-Oncologist.
Actual healthcare professional being compensated by Sanofi Genzyme. Not an Actor.
Statement reflects Dr. De Angulo's personal experience and opinion. Individual experiences may vary.

The recommended starting prophylaxis regimens are either 50 IU/kg once weekly, or 100 IU/kg once every 10 days. Dosing regimen can be adjusted based on individual response.

Children under 12 years of age may have higher Factor IX body weight-adjusted clearance, shorter half-life, and lower recovery. Higher dose per kilogram body weight or more frequent dosing may be needed.

More frequent or higher doses may be needed in children <12 years of age, especially in children <6 years of age.

Curious about ON Demand?

×

INDICATION: ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

important safety information and indication 

IMPORTANT SAFETY INFORMATION
Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Redness to the skin at the injection site may also occur.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

Your body can also make antibodies called "inhibitors" against ALPROLIX, which may stop ALPROLIX from working properly.

These are not all of the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, or if bleeding is not controlled using ALPROLIX.

INDICATION
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

important safety information and indication 

IMPORTANT SAFETY INFORMATION
Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Redness to the skin at the injection site may also occur.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

Your body can also make antibodies called "inhibitors" against ALPROLIX, which may stop ALPROLIX from working properly.

These are not all of the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, or if bleeding is not controlled using ALPROLIX.

INDICATION
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

Please see full Prescribing Information

MANUFACTURED BY
Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078

CLICK HERE TO LEARN MORE ABOUT SANOFI'S COMMITMENT TO FIGHTING COUNTERFEIT DRUGS.

Questions?

1-855-MYALPROLIX (1-855-692-5776)

Monday-Friday, 8am-8pm, ET

© 2021 Genzyme Corporation. All rights reserved. ALPROLIX is a registered trademark of Bioverativ Therapeutics Inc., a Sanofi company.

MAT-US-2021804-v3.0-06/2021 LAST UPDATED: JUNE 2021

© 2021 Genzyme Corporation. All rights reserved. ALPROLIX is a registered trademark of Bioverativ Therapeutics Inc., a Sanofi company.

MAT-US-2021804-v3.0-06/2021 LAST UPDATED: JUNE 2021

Questions?

1-855-MYALPROLIX (1-855-692-5776)

Monday-Friday, 8am-8pm, ET